抗VEGF/VEGFR在乳腺癌治疗中的研究进展(5)
[22] Baselga J， Grupo Espa？ol de Estudio Tratamiento y Otras Estrategias Experimentales en Tumores Sólidos， Roché H et？al.： SOLTI-0701： A multinational double-blind， randomized Phase IIB study evaluating the efficacy and safety of sorafenib compared to placebo when administered in combination with capecitabine in patients with locally advanced or metastatic breast cancer (BC).
[23] Isaacs C， Wilkinson M， Liu MC et？al. Phase I/II study of sorafenib with anastrozole in patients with hormone receptor positive aronatase inhibitor resistant metastatic breast cancer. Breast Cancer Res Treat， 2011， 125(1)：137-143. PMID： 20976541
[24] Burstein HJ， Elias AD， Rugo HS， et al. Phase II study of sunitinibmalate， an oral multitargeted tyrosine kinase inhibitor， in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol， 2008， 26(11)：1810–1816. PMID？：18347007
[25] Kozloff， M， Chuang E， Starr A， et al. An exploratory study of sunitinib plus paclitaxel as first-line treatment for patients with advanced breast cancer. Annals of Oncology， 2010， 21(7)： 1436-1441. PMID：20032126, http://www.100md.com(蓝天 徐谦 王晓稼)
[23] Isaacs C， Wilkinson M， Liu MC et？al. Phase I/II study of sorafenib with anastrozole in patients with hormone receptor positive aronatase inhibitor resistant metastatic breast cancer. Breast Cancer Res Treat， 2011， 125(1)：137-143. PMID： 20976541
[24] Burstein HJ， Elias AD， Rugo HS， et al. Phase II study of sunitinibmalate， an oral multitargeted tyrosine kinase inhibitor， in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol， 2008， 26(11)：1810–1816. PMID？：18347007
[25] Kozloff， M， Chuang E， Starr A， et al. An exploratory study of sunitinib plus paclitaxel as first-line treatment for patients with advanced breast cancer. Annals of Oncology， 2010， 21(7)： 1436-1441. PMID：20032126, http://www.100md.com(蓝天 徐谦 王晓稼)